<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830425</url>
  </required_header>
  <id_info>
    <org_study_id>PI15/00552</org_study_id>
    <nct_id>NCT02830425</nct_id>
  </id_info>
  <brief_title>Potentially Inappropriate Prescription Associated to Multimorbidity</brief_title>
  <acronym>PIMyC</acronym>
  <official_title>Potentially Inappropriate Prescription Associated to Multimorbidity, Using the Explicit STOPP-START (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions/Screening Tool to Alert Doctors to the Right Treatment) Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Galdakao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorci Hospitalari de Vic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <brief_summary>
    <textblock>
      A prospective multicenter cohort study in 5 hospitals in Spain will be initiated in 2016.

      Objectives:

        1. To estimate and describe patterns of multimorbidity and polypharmacy in patients over 64
           admitted for a chronic disease exacerbation.

        2. To analyze the potentially inappropriate prescribing (PPI) drugs according to STOPP /
           START (SS) criteria.

        3. To evaluate the relationship between multimorbidity and PPI and adverse medication (RAM)
           preventable reaction.

      The cohort will include 800 patients &gt;64 years admitted in internal medicine and / or
      geriatric department of 5 hospitals of the National Health Service. Application of the SS
      criteria (released in 2015) on admission and at discharge, and collection of demographic and
      clinical variables including comorbidities, baseline chronic medication, geriatric syndromes,
      functional capacity and RAM. Descriptive analysis and bivariate parametric or nonparametric
      tests will be applied to analyze relationship between morbidity, polypharmacy, SS criteria
      and RAM. Intraobserver agreement will be assessed for SS criteria. Multiple regression
      techniques will be applied, where the dependent variable will be the PPI or the RAM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Potentially inappropriate medication, according to STOPP-START explicit criteria</measure>
    <time_frame>At study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Potentially inappropriate medication, according to STOPP-START explicit criteria</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with polypharmacy</measure>
    <time_frame>At study entry</time_frame>
    <description>Polypharmacy=more than 5 chronic medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with any treatment-related adverse events (ADR), according to the Wills &amp; Brown classification</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of different Patterns of multimorbidity in chronic patients, according to clusters or associations of different chronic conditions</measure>
    <time_frame>At study entry</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly with any chronic condition admitted in Internal Medicine or Geriatrics department
        because of an exacerbation of any chronic condition
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient admitted to the Internal Medicine or Geriatrics department

          -  Admitted to hospital because of an exacerbation of any previous chronic condition

        Exclusion Criteria:

          -  Terminal ill patients at admission

          -  Patients with lower forecast life than 1 year

          -  Patient admitted to the hospital only because an acute problem

          -  In patient home care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisa Baré, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacio Parc Taulí</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marisa Baré, MD, MPH, PhD</last_name>
    <phone>34 93 7458245</phone>
    <email>mbare@tauli.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Corporacio Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Baré, MD, MPH, PhD</last_name>
      <phone>34 93 7458245</phone>
      <email>mbare@tauli.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Marisa Baré, MD, MPH, PhD</investigator_full_name>
    <investigator_title>Cancer Screening-Epidemiology Coordinator</investigator_title>
  </responsible_party>
  <keyword>Multimorbidity</keyword>
  <keyword>Polypharmacy</keyword>
  <keyword>Appropriateness</keyword>
  <keyword>STOPP</keyword>
  <keyword>START</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

